A5100370194- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Coronary Interventions and Diagnostics
- Cardiac pacing and defibrillation studies
- Cardiac, Anesthesia and Surgical Outcomes
- Traumatic Brain Injury and Neurovascular Disturbances
- Cardiac Arrhythmias and Treatments
- Mechanical Circulatory Support Devices
- Atrial Fibrillation Management and Outcomes
- Advanced MRI Techniques and Applications
- Orthopaedic implants and arthroplasty
- Anesthesia and Neurotoxicity Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Heart Rate Variability and Autonomic Control
- Cardiac Ischemia and Reperfusion
- Traditional Chinese Medicine Studies
- Pneumonia and Respiratory Infections
- Healthcare and Venom Research
- Pulmonary Hypertension Research and Treatments
- Neurological Disease Mechanisms and Treatments
- Cardiac and Coronary Surgery Techniques
University of British Columbia
2016-2025
St. Paul's Hospital
2015-2025
Vancouver General Hospital
2016-2025
University of Rochester
2020-2025
Second Affiliated Hospital of Zhejiang University
2025
Nanchang University
2025
Valve (United States)
2016-2025
Ministry of Public Security of the People's Republic of China
2022-2024
St. Paul's Hospital
2014-2024
City of Hope
2024
Background— Percutaneous aortic valve replacement represents an endovascular alternative to conventional open heart surgery without the need for sternotomy, aortotomy, or cardiopulmonary bypass. Methods and Results— Transcatheter implantation of a balloon-expandable stent using femoral arterial approach was attempted in 50 symptomatic patients with severe stenosis whom there consensus that risks were very high. Valve successful 86% patients. Intraprocedural mortality 2%. Discharge home...
Transcatheter aortic valve implantation is an alternative to open heart surgery in patients with stenosis. However, long-term data on a programmatic approach remain sparse.Transcatheter was performed 168 (median age, 84 years) the setting of severe stenosis and high surgical risk. Access transarterial (n=113) or, presence small iliofemoral artery diameter, transapical (n=55). The overall success rate 94.1% this early experience. Intraprocedural mortality 1.2%. Operative (30-day) 11.3%, lower...
Aortic valve replacement with cardiopulmonary bypass is currently the treatment of choice for symptomatic aortic stenosis but carries a significant risk morbidity and mortality, particularly in patients comorbidities. Recently, percutaneous transfemoral implantation has been proposed as viable alternative selected patients. We describe our experience new, minimally invasive, catheter-based approach to via left ventricular apical puncture without or sternotomy.A anterolateral intercostal...
The majority of prosthetic heart valves currently implanted are tissue that can be expected to degenerate with time and eventually fail. Repeat cardiac surgery replace these is associated significant morbidity mortality. Transcatheter valve implantation within a failed bioprosthesis, "valve-in-valve" procedure, may offer less invasive alternative.Valve-in-valve implantations were performed in 24 high-risk patients. Failed aortic (n=10), mitral (n=7), pulmonary (n=6), or tricuspid (n=1)...
Background— The objective of this study was to evaluate the timing, predictive factors, and prognostic value cerebrovascular events (CVEs) after transcatheter aortic valve implantation. Methods Results— included 1061 consecutive patients who underwent implantation with a balloon-expandable (64%) or self-expandable (36%) valve. CVEs were classified as acute (≤24 hours), subacute (1–30 days), late (>30 days). occurred in 54 (5.1%; stroke, 4.2%) within 30 days (acute 54% cases). predictors...
Few studies have evaluated the clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with bicuspid stenosis (AS). Particularly, limited data exist comparing results TAVR new-generation devices versus early-generation devices. This study sought to evaluate for AS early- and The Bicuspid Registry is an international multicenter enrolling consecutive undergoing between April 2005 May 2015. Of 301 patients, 199 (71.1%) were treated (Sapien XT [Edwards Lifesciences...
Background: The current treatment of choice for symptomatic aortic stenosis is valve replacement (AVR) with cardiopulmonary bypass (CPB), but AVR associated significant operative morbidity and mortality in elderly patients multiple co-morbid conditions. We recently reported the first successful implantation procedure (AVI) via a mini-thoracotomy left ventricular apical puncture without bypass. now report 6-month follow-up our initial seven patients. Methods: Seven (77 ± 10 years old) were...